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Key Points
•Human type 3 ILCs
acquire features of
early differentiated NK
cells upon cytokine
stimulation.
• IL-12 and IL-15–
differentiated human
ILC3s acquire cytotox-
icity and kill leukemic
targets.
Type 3 innate lymphoid cells (ILC3s) fulﬁll protective functions at mucosal surfaces via
cytokine production. Although their plasticity to become ILC1s, the innate counterparts of
type 1 helper T cells, has been described previously, we report that they can differentiate into
cytotoxic lymphocytes with many characteristics of early differentiated natural killer (NK)
cells. This transition is promoted by the proinﬂammatory cytokines interleukin 12 (IL-12)
and IL-15, and correlates with expression of the master transcription factor of cytotoxicity,
eomesodermin (Eomes). As revealedby transcriptomeanalysis andﬂowcytometric proﬁling,
differentiated ILC3s express CD94, NKG2A, NKG2C, CD56, and CD16 among other NK-cell
receptors, andpossess all components of the cytotoxicmachinery. These characteristics allow
them to recognize and kill leukemic cells with perforin and granzymes. Therefore, ILC3s can
be harnessed for cytotoxic responses via differentiation under the inﬂuence of proinﬂam-
matory cytokines.
Introduction
Adaptive immune responses are orchestrated by helper T-cell subsets that tailor the immune system’s
effector function for optimal restriction of pathogenic threats.1 Along these lines, CD41 T helper 1 (Th1)
cells aid in the priming and maintenance of cytotoxic CD81 T cells during cell-mediated immune control
of viruses and tumors, CD41 Th2 cells assist B cells to mount humoral immune responses to parasites,
and CD41 Th17 cells defend mucosal barriers by stimulating epithelial cells and recruiting neutrophils. It
has been suggested that innate lymphoid cells (ILCs) represent the innate counterpart to these polarized
Th-cell responses, whereby type 1 ILCs (ILC1s) fulfill some of the functions of Th1, ILC2s of Th2, and
ILC3s of Th17 cells.2-4 Indeed, by both lineage-defining transcription factors and hallmark cytokines, the
ILC subsets seem to resemble Th-cell subsets. ILC1s express T-box transcription factor T-bet and
produce interferon-g (IFN-g); ILC2s carry the highest levels of GATA-binding protein 3 (GATA3) and
produce interleukin-4 (IL-4), IL-5, IL-9, and IL-13; and ILC3s harbor RAR-related orphan receptor g T
(RORgt) and produce IL-22. However, this clear structure of discrete ILC lineages has been challenged
by recent reports that both human ILC2s and ILC3s can differentiate into helper ILC1s under
inflammatory conditions in the presence of IL-12.5-10 Moreover, mass cytometric and single-cell
transcriptomic studies of human ILCs have called into question the existence of a helper ILC1 subset
distinct from natural killer (NK) cells.11,12
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In contrast to ILCs, NK cells are considered the innate counterpart
of cytotoxic CD81 T cells as they express cytolytic molecules, like
perforin and granzymes, and the transcription factor Eomes.13-15
NK cells do not develop exclusively in the bone marrow and seem to
undergo functional maturation in the periphery.16 Interestingly, NK
developmental intermediates found in secondary lymphoid tissues,
namely Lineage2CD1171CD942 stage 3 and CD1172/1CD941
NKp802 stage 4a cells, share features with ILC3s such as IL-22
production.17,18 Moreover, RORgt-expressing precursors might
give rise to NK cells.18,19 Therefore, these studies, as a second line
of evidence, also suggest that cells with phenotypic and functional
similarities to ILC3s can give rise to NK cells. To investigate this
question in more detail, we isolated ILC3s from pediatric tonsils and
secondary lymphoid and intestinal tissues of mice with reconsti-
tuted human immune system components and exposed them to
proinflammatory cytokines. We report here that human cytokine-
differentiated ILC3s transcriptionally and phenotypically resemble
early differentiated NK cells and upregulate their cytolytic machinery
under inflammatory conditions. Thus, cytotoxic innate lymphocytes
can develop from ILC3s, and IL-12 plus IL-15 are the most efficient
cytokines at inducing this differentiation.
Materials and methods
Tissue collection
Tonsils were collected from patients undergoing tonsillectomy at
the University Children’s Hospital of Zu¨rich and the University
Hospital Zu¨rich. Human fetal liver tissues were procured from
Advanced Bioscience Resources. Tissues were collected after
patients provided informed consent in accordance with the
Declaration of Helsinki. All studies involving human samples were
reviewed and approved by the cantonal ethical committee of Zu¨rich,
Switzerland (protocol no. KEK-StV-Nr.19/08).
Humanized mice
Humanized mice were generated as described in supplemental
Materials and methods.
Cell lines
K562, 721.221, and Jurkat cells were maintained in R10 (RPMI 1640
with 10% fetal calf serum; Bioswisstec/Gibco) and antibiotics
(penicillin [50 U/mL], streptomycin [50 mg/mL]). All culture reagents,
unless otherwise indicated, were purchased from Life Technologies.
Cell isolation and purification
Cell isolations and purifications were performed as described in
supplemental Materials and methods.
Flow cytometry and cell sorting
All antibodies used for flow cytometric analysis are listed in supplemental
Table 1. Dead cells were excluded with a LIVE/DEAD Fixable Aqua or
Near-IR kit (Invitrogen). For detecting cell surface markers, cells were
stained for 20minutes on ice. For cytokine/granzyme B (GzmB)/perforin
detection, cells were fixed and permeabilized with aCytofix/Cytoperm kit
fromBDBiosciences and stained for 30minutes on ice. For intranuclear
stainings, a Foxp3/Transcription Factor Staining Buffer Set from
eBioscience was used, and cells were stained for 45 minutes at room
temperature or at 4°C overnight. Data were acquired on an LSR II
Fortessa cytometer (BD Biosciences). For cell sorting, a FACSAria III
instrument (BD Biosciences) was used. Analysis was performed using
FlowJo software (TreeStar).
Expansion of ILCs
ILCs were seeded with irradiated allogeneic peripheral blood
mononuclear cells and the B-lymphoblastoid cell line 721.221 in the
presence of phytohemagglutinin (PHA-L) (2.5 mg/mL; EMD
Millipore) and cytokines (Peprotech); the latter were replenished
every 3 to 4 days starting at day 5. ILCs were stimulated with IL-2
(600 U/mL), IL-7 (10 ng/mL), IL-12 (50 ng/mL), IL-15 (20 ng/mL),
IL-18 (50 ng/mL), or combinations thereof as specified in the
respective figures. NK cells were expanded with IL-15 (20 ng/mL).
Cultures were maintained in RPMI 1640 plus 10% human serum
AB (Bioconcept) plus L-glutamine (2 mM; Gibco) plus gentamicin
(20 mg/mL) at 37°C with 5% CO2 for 2 to 5 weeks. For single-cell
cultures, ILC3s were single-cell sorted into 96-well plates preseeded
with irradiated Cell Trace Violet–labeled feeders, and cultured in the
presence of IL-2 plus IL-7 or IL-12 plus IL-15 for 21 days.
Cytokine production, degranulation, and
cytotoxicity assays
For flow cytometric analyses, K562 cells were labeled with Cell
Trace Violet (Invitrogen).
For the analysis of cytokine production and cytotoxic effector
molecule release, cultured ILCs were stimulated for 4 hours with
K562 cells at an effector-to-target (E:T) ratio of 1:1, with 10 ng/mL
phorbol myristate acetate (PMA) and 500 ng/mL ionomycin (both
from Sigma-Aldrich) or in addition with IL-1b (50 ng/mL) and IL-23
(50 ng/mL). After 45 minutes, 2 mM monensin (eBioscience) and
5 mg/mL brefeldin A (Sigma-Aldrich) were added.
For degranulation assays, cultured ILCs were coincubated with
K562 cells at a ratio of 1:1 in the presence of fluorescein
isothiocyanate–conjugated anti-CD107a monoclonal antibody
(mAb). After 1 hour, degranulation was blocked by addition of
GolgiStop (BD Biosciences); after a total of 4 hours, CD107a
surface expression on effector cells was assessed.
To detect spontaneous degranulation or constitutive expression of
cytokines/cytotoxic effectors, a control without target cells was
included.
Cytolytic activity was measured using a lactate dehydrogenase
cytotoxicity assay (ThermoFisher) and calculated according to the
manufacturer’s instructions. K562 or Jurkat cells (23 103 cells per well)
were incubated with effectors at a 10:1 ratio for 18 hours, unless
otherwise stated. For blocking experiments, anti-TRAIL (2E5; 1 mg/mL),
anti-FasL (NOK-1; 10 mg/mL), and control mouse immunoglobulin G1
(IgG1 [MOPC-21]; 10 mg/mL) antibodies were used. Antibodies were
titrated on Jurkat cells using purified effector molecules (data not
shown). For perforin-mediated cytotoxicity inhibition, effector cells were
preincubated for 2 hours with concanamycin A (CMA; 10 nM).
RNA sequencing
Total RNA was isolated using the PicoPure RNA isolation kit
(ThermoFisher). NKp441 ILC3s were either transferred to lysis
buffer right after sorting or differentially cultured for 3 weeks.
Samples were stored at 280°C until use. Freshly isolated splenic
ILC3s (2000-15 000), tonsillar ILC3s (900-9 000), and expanded
cells (10 000) were used for RNA isolation. Quality control and
sequencing was performed by the Genomics Facility Basel
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(Department of Biosystems Science and Engineering, Eidgeno¨ssi-
sche Technische Hochschule Zu¨rich [ETH], Basel, Switzerland).
Adapter sequence (AAGCAGTGGTATCAACGCAGAGT) was
trimmed from obtained single-end RNA sequencing (RNA-seq)
reads (51 mer) using the preprocessReads function from the QuasR
package (Gaidatzis et al,20 version 1.14.0, R version 3.3.1).
Preprocessed reads were mapped to the human genome assembly,
version hg19, with RNA-STAR,21 with default parameters except for
reporting only 1 hit in the final alignment files for multimappers
(outSAMmultNmax51) and allowing only reads after filtering to pass
into the spliced junction table (outFilterType5“BySJout”). Using
RefSeq messenger RNA (mRNA) coordinates from the University of
California Santa Cruz (UCSC; https://genome.ucsc.edu) and the
qCount function from the QuasR package, we quantified gene
expression as the number of reads that started within any annotated
exon of a gene. The differentially expressed genes were identified using
the edgeR package (Robinson et al,22 version 3.16.5). Genes with a
false discovery rate smaller than 0.05 and a minimum log2 fold change
of 61 were used for downstream analysis. The obtained data sets
(GSE99246) were compared with the gene expression analysis of
Montaldo et al23 (GSE63197). For every gene, the probe with highest
variance across samples was kept. The differential expression analysis
between NK and ILC3 cells was calculated using the “limma”
package.24 Patient structure was taken into account as a covariate.
Statistical analysis
Comparison between differentially cultured ILCs was done via
paired Student t tests. The Spearman coefficient was used to
determine the correlation between cytotoxicity and frequency of the
indicated populations within cultures. Statistical analysis was
performed using Prism software (GraphPad). Data are displayed
as mean 6 standard deviation (SD), unless otherwise stated.
Results
ILC3s in tonsils and humanized mouse tissues
The findings that human NK cells can be derived from RORgt-
expressing precursors18,19 and the controversial existence of an
ILC1 population distinct from NK cells in humans11 suggest
fundamental species differences in ILC biology25-27 and the need
for a better experimental model to study human ILC biology. To that
end, we characterized ILCs, specifically ILC3s and NK cells, in
NOD-scid Il2rgnull mice engrafted with human CD341 hematopoi-
etic progenitor cells, denoted as huNSG mice (human reconstitu-
tion shown in supplemental Figure 1). We were able to detect
ILC3s, identified as CD1271CD1171Lineage2(CD32CD192
CD142CD162FceRIa2CD342TCRa/b2TCRg/d2CD2942) cells,
across various lymphoid and nonlymphoid organs of huNSG mice
(Figure 1 and data not shown) and focused on spleen and small
intestine (SI) in our further analysis. In parallel, we analyzed ILC3s from
human tonsils, where they are readily found.11 ILC3s and NK cells,
sorted as NKp461CD941CD1272Lineage2 cells, were similarly
represented in tonsils (18% and 24% of ILCs of interest, respectively)
and the SI of huNSG mice (both 36%), whereas in huNSG spleens
ILC3 frequency was more than twofold lower (22% vs 54% of ILCs of
interest) (Figure 1B). Spleen and SI not only differed in relative subset
distribution, but also in ILC frequency amongCD451 cells (Figure 1C).
Consistent with human data,9,11 ILC3s were enriched in the intestine
but were rare in spleen (6%-9% and circa 0.2% of human leukocytes,
respectively). No differences were observed between huNSG mice
with and without a HLA-A2 transgene. Thus, ILC3s develop in huNSG
mice and this model can be exploited for studying human ILC
development and function.
IL-12 and IL-15 induce phenotypic NK-cell markers
on ILC3s
ILC3s show flexibility in their functional program and can shift
toward IFNg production depending on the cytokine milieu.9,10,28,29
Likely because ILC3s and NK cells are generated through mutually
exclusive pathways in mice, human ILC3 plasticity toward an NK
program has not been extensively investigated. To address this,
tonsillar NKp441 ILC3s were isolated and cultured with IL-2 and
IL-7 to obtain sufficient cell numbers for in vitro experiments. After
repurification to remove any NK cells, ILC3s were incubated with
the type 1 polarizing cytokines IL-2, -12, -15, -18, or combinations
thereof. Exposure to IL-12 resulted in a low but consistent increase
in CD941 cells, which also upregulated T-bet and downregulated
RORgt. Modulation of the ILC3 profile by IL-12 has been previously
demonstrated,9,10 but, in contrast to these studies and mouse
data,25 we observed induction of Eomes, a transcription factor
associated solely with cytotoxic lymphocytes (supplemental
Figure 2A). Although IL-12 and IL-15 alone or in combination
promoted differentiation of Eomes1CD941 cells, additional T-bet
induction was primarily observed in IL-12–containing conditions
and synergized with IL-15 (supplemental Figure 2B). Hence this
cytokine combination was used for further investigations into the
properties of differentiated cells. In line with the data from tonsils,
cultures of NKp441 ILC3s derived from huNSG spleen and SI in
the presence of IL-12 and IL-15 led to the appearance of bona fide
CD941Eomes1 NK cells (Figure 2; experimental outline shown in
supplemental Figure 3A). Similar results were also obtained with
NKp442NKp462, referred to as NCR2, ILC3s (not tested for SI)
(Figure 2). Although Eomes1CD941 cells were also generated with
IL-2 and IL-7, even more so when ILC3s were purified from freshly
isolated tonsillar mononuclear cells, additional T-bet induction was
more prominent in IL-12 plus IL-15 conditions (supplemental
Figure 3B). Thus, IL-2 and IL-15 might have similar roles in this
process with differences between cultures generated from fresh
and cryopreserved cells, possibly arising from reduced sensitivity to
IL-2 or reduced viability of IL-2–responsive ILC3 cells after freezing/
thawing. Interestingly, only a fraction of Eomes1 cells coexpressed
CD94 or T-bet (Figure 2). Instead, a considerable population
retained RORgt expression (supplemental Figure 3C) and thus
displayed an intermediate phenotype between ILC3s and NK cells.
Furthermore, we observed the same effects in clonal assays. Single
ILC3s gave rise to Eomes1CD942 and Eomes1CD941T-bet6
cells and their frequencies were comparable to the bulk cultures,
with, however, larger variations. Percentages of Eomes1RORgt2,
Eomes1RORgt1, Eomes2RORgt1 cells were also similar between
single-cell and bulk cultures (Figure 3). Collectively, IL-12 plus IL-15
stimulation of ILC3s led to the differentiation of phenotypically
distinct populations with features of NK cells.
IL-12 and IL-15 culture of ILC3s leads to a
transcriptional profile reminiscent of early
differentiated NK cells
To further study how cytokine treatment modifies the ILC3 profile,
we performed RNA-seq of IL-12 plus IL-15–treated cultures of
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NKp441 ILC3s in comparison with IL-2 plus IL-7–expanded and
untreated cells. Tonsillar- and huNSG-derived splenic NKp441 ILC3s
were used as cell sources. In a principal component analysis, samples
formed individual clusters dependent on their tissue origin and cytokine
exposure with the exception of those cultured with IL-12 and IL-15
(Figure 4A), which clustered together, indicating that on a transcriptional
level this stimulation overrides any tissue-specific differences. For
example, we observed that freshly sorted spleen-derived ILC3s had
more transcripts for lymphotoxin-a (LTA), lymphotoxin-b (LTB), and
tumor necrosis factor (TNF) compared with those isolated from tonsils,
which in contrast showed abundant IL22 expression (Figure 4B), in line
with a previous report.30 In both populations, we detected expression of
IL1R1, IL23R, TNFSF11 (encoding TRANCE), andCCL20, which are
genes selectively transcribed in ILC3s among innate lymphocytes.12
Taken together, ILC3s isolated from huNSG spleens were similar to
those derived from human tissues, suggesting that huNSG mice
recapitulate many aspects of human ILC biology.
Despite the spatial principal component analysis proximity of ILC3s
stimulated with IL-2 and IL-7 to untreated cells (Figure 4A), IL-2 plus
IL-7–expanded cells upregulated EOMES, TBX21, PRF1 (perforin),
and transcripts encoding granzymes, in particular, GZMA in tonsils
and GZMK in spleen (supplemental Figure 4B-C), indicating that
they shifted away from an ILC3 transcriptional program.
When cultured with IL-12 and IL-15, ILC3s upregulated genes that
encode NK-related markers such as CD56, CD94, NKG2A, NKG2C,
DNAM-1/CD226, and CD2 (Figure 4D). Surprisingly, transcripts for
NKG2D (KLRK1) were lower upon IL-12 and IL-15 stimulation
compared with unstimulated and IL-2 plus IL-7 conditions. Furthermore,
splenic untreated cells already expressed genes encoding the NK-
associated receptors 2B4 (CD244), KLRG1, and 4-1BB (TNFRSF9).
FCGR3A (CD16) expression was also increased relative to untreated
cells, however, it was diverse across samples and tissues and rarely
detected on the protein level (data not shown). In contrast, CD56 was
found on the majority of cells in both conditions. We also assessed
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Figure 1. ILC3s in pediatric tonsils and spleens of huNSG mice. (A) Sorting strategy for isolation of viable (Aqua Live/Dead2) human (huCD451) ILCs: after exclusion
of cells positive for CD3, CD19, CD14, CD16, FceRIa, CD34, TCRa/b, TCRg/d, and CD294, ILC3s were identified as CD1271CD1171 and selected for NKp441 (red) or
NKp442NKp462 (dark blue, referred to as NCR2). NK cells were sorted as NKp461CD1272CD941 cells (yellow). Shown is a representative spleen sample, magnetic-
activated cell sorting (MACS)–depleted for CD19, CD14, CD4, and CD8. (B) Pie charts show mean frequency (6SD) of the indicated populations among ILCs of interest, as
defined in panel A, within spleen (N 5 26 from 20 human fetal liver [HFL] donors with 2 to 15 mice per donor), small intestine (SI) (N 5 12 from 9 HFL donors with 4-15
pooled mice), and pediatric tonsils (N 5 16). (C) Mean frequency (6SD) of the indicated populations among huCD451 cells derived from spleen (N 5 3, 1-8 mice per HFL
donor) and SI (samples as in panel B). FSC-A, forward scatter area; FSC-H, forward scatter height; SSC-A, side scatter area; TCR, T-cell receptor.
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Figure 2. IL-12 and IL-15 induce phenotypic NK-cell markers on ILC3s.
NKp441 and NCR2 ILC3s derived from pediatric tonsils or the indicated
humanized mouse tissues were cultured with IL-2 plus IL-7 or IL-12 plus IL-15
and analyzed for expression of Eomes, CD94, and T-bet by flow cytometry.
Tonsillar and splenic ILC3 cultures were maintained for 3 weeks, intestinal
cultures for 4 weeks. (A) Representative flow cytometry plots of expanded
tonsillar NKp441 ILC3s and NK cells, each row gated on viable ILCs. (B)
Frequency of the indicated subsets in cultures. For tonsils, N 5 9 and N 5 5 for
NKp441 and NCR2 ILC3s, respectively. For spleen, N 5 14 (10 HFL donors,
2-8 mice per donor) and N 5 6 (6 HFL donors, 2-8 mice per donor) for NKp441
and NCR2 ILC3s, respectively. For SI, N 5 3 (3 HFL donors, 4-5 mice each).
not significant (ns), P . .05; *P , .05; **P , .01; ***P , .001 using the paired
Student t test.
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Figure 3. Single NKp441 ILC3s give rise to NK-like cells. Single-cell sorted tonsil-derived NKp441 ILC3s were cultured on irradiated Cell Trace Violet–stained feeders
in the presence of IL-2 plus IL-7 or IL-12 plus IL-15 and each well was individually assessed by flow cytometry after 3 weeks. (A) Representative flow cytometry plots of 2
clonal cultures. (B) Comparison between the frequency of the indicated populations in ILC3 clones and the corresponding bulk-sorted cultures. Data from 3 independent
donors (mean in red 6 SD, bars indicate median).
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NKG2A, NKG2C, and CD2 expression by flow cytometry and
observed upregulation in IL-12 and IL-15–treated ILC3s (Figure 4E).
KIR3DL3 expression partially overlapped with that of FCGR3A in
spleen and less so in tonsils, whereas other inhibitory killer
immunoglobulin-like receptors had a lower and more scattered
expression pattern in spleen and were absent in tonsil (Figure 4D
top). Hence, IL-12 and IL-15–stimulated ILC3s acquired a profile
reminiscent of the previously published early differentiated NK-cell
phenotype.31,32 Concurrently, these showed enrichment of genes
encoding IFNg, macrophage inflammatory protein-1a (MIP-1a), MIP-1b,
and IL-8 (in spleen) as well as subunits of the IL-2/-12/-15/-18
receptors (Figure 4B), which suggested that IL-12 and IL-15 primed
ILC3s toward a type 1 inflammatory response. When examining their
cytotoxic potential, we found that untreated splenic ILC3s had low
constitutive TNFSF10 (encoding TRAIL) expression, which was
unchanged after exposure to IL-12 and IL-15. Conversely, this
stimulation elevated TNFSF10 transcripts in tonsillar cells. Furthermore,
IL-12 and IL-15 increased EOMES, FASLG, and granzyme expression
compared with IL-2 and IL-7–cultured cells, whereas PRF1 levels were
similar between the 2 culture conditions (Figure 4C; supplemental
Figure 4B). This IL-12 and IL-15–driven differentiation to an NK-
cell–like phenotype was further supported by comparison with a
previously published transcriptome analysis of ILC3s and NK cells.23
This demonstrated that hallmark functional genes of NK cells correlated
with genes upregulated in IL-12 and IL-15–differentiated ILC3 cultures
(supplemental Figure 4A). To further characterize the functional
properties of NK-cell–like ILC3-derived cells, we next analyzed their
response toward leukemic cells.
IL-12 and IL-15 induce type 1 cytokine production
in ILC3s
We first assessed the IFNg and TNFa expression in response to
stimulation with a classical NK-cell target, the erythroleukemic cell
line K562, as well as with PMA and ionomycin (PMAi). K562 cells
induced TNFa, which was detected both in CD1171 and CD1172
cells after differentiation (Figure 5; supplemental Figure 5A). In
contrast, IFNg expression was solely observed in IL-12 plus IL-15
cultures and coincubation with K562 cells triggered only a weak
IFNg response in differentiated ILC3s in comparison with that
induced by PMAi (Figure 5). Stimulation with IL-23 and IL-1b in
addition to PMAi increased IL-22 expression in both splenic and
tonsillar ILC3s from either culture (supplemental Figure 5B), further
indicating that a fraction of ILC3s maintained their phenotypic and
functional program. Altogether, IL-12 and IL-15 induced a type 1
cytokine profile in ILC3s, a finding consistent with previous reports
for differentiated ILC3 as well as ILC2 cells.5-10
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Figure 5. IL-12 and IL-15 induce a type 1 cytokine profile in ILC3s. Splenic NKp441 ILC3s, cultured for 4 weeks with IL-2 and IL-7 or IL-12 and IL-15, were stimulated
for 4 hours with K562 target cells or PMAi and analyzed for cytokine production. Flow cytometric analysis of IFNg and TNFa expression in IL-12 and IL-15–treated cells (A-B)
and quantification of IFNg- and/or TNFa-expressing cells in the indicated conditions (C). N 5 6 (3 HFL donors, 4 mice per donor). Red lines show mean and box-and-whiskers
plot extend minimum (min) to maximum (max) with black lines representing median value. ns, P . .05; *P , .05 using paired Student t tests.
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Upregulation of the cytotoxic machinery in ILC3s upon
IL-12 and IL-15 exposure
As transcriptional profiling revealed expression of cytotoxic effector
molecules, we investigated protein expression of GzmB and perforin in
differentially cultured ILC3s (Figure 6A). Surprisingly, perforin was barely
detectable in IL-12 and IL-15–treated cells but the addition of K562
cells resulted in a rapid release as indicated by reduced staining.
Consistent with abundant mRNA transcripts in IL-12 and IL-15 cultures,
GzmB was expressed in significantly more cells at the protein level.
To investigate the cytolytic potential of ILC3s, we evaluated their
capacity to degranulate toward K562 cells. After 4-hour stimulation,
degranulation levels in total expanded cells were similar in the 2
conditions (circa 13%) (data not shown). Therefore, we checked CD107
expression among the various subsets (Figure 6B). Eomes1 cells,
irrespective of culture conditions, showed higher degranulation ability.
Thus, ILC3s treated with IL-12 and IL-15 acquired cytotoxic granule
proteins, associated with Eomes expression, and Eomes1 cells
preferentially degranulate in response to leukemic cells.
Cytotoxicity of IL-12 and IL-15–cultured ILC3s toward
classical NK-cell targets
As IL-2 and IL-7–treated cells were devoid of GzmB and perforin
protein expression but showed some surface CD107 expression
upon K562 coincubation, we directly assessed target cell killing.
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Figure 6. Upregulation of cytotoxic machinery in ILC3s
upon IL-12 and IL-15 exposure. Splenic NKp441 ILC3s
were cultured for 4 weeks with IL-2 and IL-7 or IL-12 and IL-15
and stimulated for 4 hours with K562 target cells or PMAi.
(A) Flow cytometric analysis (top) and quantification (bottom) of
total GzmB or perforin expression in cultures. Fluorescence-
activated cell sorting (FACS) plots shown for unstimulated
expanded ILC3s and NK cells. Red lines show mean and box-
and-whiskers plot extend min to max with black lines represent-
ing median value. (B) Degranulation of bulk cultures. D%
CD107 indicates the difference in degranulation with and
without K562 coincubation. N 5 6 (3 HFL donors, 4 mice per
donor). ns, P . .05; *P , .05; **P , .01; ***P , .001 using
the paired Student t test.
26 DECEMBER 2017 x VOLUME 1, NUMBER 27 ILC3s DIFFERENTIATE INTO CYTOTOXIC NK-LIKE CELLS 2687
Differentially stimulated bulk ILC3 cultures were incubated with
K562 cells for 18 hours to allow for both perforin-dependent and
-independent cytotoxicity, because TRAIL expression was detected
at the transcriptional level in some of the differentiated
innate lymphocyte cultures. Expanded tonsillar NKp441 ILC3s
acquired a twofold higher cytotoxicity when stimulated with IL-12
and IL-15, whereas NCR2 ones showed variability in their cytolytic
potential (Figure 7A). Splenic expanded NKp441 ILC3s from both
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Figure 7. Cytotoxicity of IL-12 and IL-15–cultured ILC3s toward the classical NK-cell target K562 is perforin-mediated. ILC3s were expanded for 3 weeks with
IL-2 and IL-7 or IL-12 and IL-15 and the cytolytic potential of bulk cultures against K562 targets was assessed after 18-hour stimulation at a 10:1 E:T ratio using a lactate
dehydrogenase (LDH) cytotoxicity assay. (A) Cytotoxicity of expanded tonsillar and splenic NKp441 and NCR2 ILC3s. For tonsils, N 5 6 and N 5 3 for NKp441 and NCR2
ILC3s, respectively. For spleen, N 5 3 and N 5 6 for NKp441 and NCR2 ILC3s, respectively; each sample is an individual HFL donor with 2 to 8 mice pooled. Expanded NK
cells from the same donors were used as positive controls. (B) Cytolytic activity of IL-12 plus IL-15–expanded tonsillar NKp441 ILC3s and NK cells in the presence of medium
alone, mouse IgG1 isotype, anti-TRAIL antibody, CMA (effectors were preincubated for 2 hours) or a combination of the latter, N 5 5 except for the last condition in which
data were obtained from 3 donors. (C) Correlation between frequency of the above-stated populations and cytotoxicity for tonsillar NKp441 ILC3 cultures. ns, P . .05;
*P , .05; ***P , .001 using paired Student t test in panels A and B or Spearman correlation in panel C. r, Spearman rank correlation coefficient.
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culture conditions showed moderate cytotoxicity, whereas NCR2
ILC3s had a threefold increase in cytolytic activity after IL-12 and
IL-15 relative to IL-2 and IL-7 exposure. We analyzed the latter
following 4 and 18 hours of coincubation at different E:T ratios
(supplemental Figure 6A). Longer coculture at higher E:T ratios
enhanced target cell lysis, which reached a similar level compared with
NK cells at a 20:1 E:T ratio, despite the heterogeneity of the ILC3
cultures. Thus, IL-12 and IL-15–induced cytolytic activity in ILC3 cells.
Similar to NK cells, this cytotoxicity was to a large extent mediated by
perforin and granzymes because inhibition with concanamycin A
reduced killing of K562 cells by 60%, whereas antibody-mediated
blocking of TRAIL did not reduce leukemic cell death (Figure 7B). We
did not test blocking of TNF and FasL because we were not able to
induce K562 cell death with agonistic reagents that stimulate these
pathways (data not shown). In contrast, the T-cell leukemia cell line
Jurkat is sensitive to apoptosis-inducing cell death (data not shown),
and IL-12 and IL-15–stimulated ILC3s seemed to use numerous
mechanisms to induce Jurkat cell death, including but not restricted to
perforin, FasL, and TRAIL (supplemental Figure 6B). Therefore, IL-12
and IL-15–differentiated ILC3s seem to use all transcriptionally
upregulated cytotoxicity molecules for tumor cell lysis. Next, we aimed
to identify the subset of differentiated ILC3s that mediates the
cytotoxicity in the K562 cocultures. Considering both tonsillar NKp441
(Figure 7C) and splenic NCR2 (supplemental Figure 6C) ILC3
cultures, the degree of cytotoxicity correlated best with Eomes1T-bet1
cells. Taken together, our data indicated that IL-12 and IL-15 promoted
acquisition of both phenotypic and functional traits associated with NK
cells, which were strongly associated with the expression of Eomes.
Discussion
Our studies demonstrate that human ILC3s give rise to Eomes1T-
bet1/2CD941/2 cytotoxic innate lymphocytes that also express
NK-cell receptors like CD56, NKG2A, NKG2C, and CD16. In
addition, they produce the hallmark cytokines of NK cells, TNFa and to a
lesser extent IFNg, and upregulate cytotoxic molecules, primarily
granzymes. They kill target cells less efficiently than classical NK cells
and with slower kinetics. This could be due to the heterogeneity
of the differentiated cells, containing smaller subsets of truly
cytotoxic lymphocytes. However, these seem to kill with perforin/
granzymes, FasL, and TRAIL–mediated cytotoxicity, similar to NK cells.
Acquisition of cytolytic traits is augmented by stimulation with IL-12 and
IL-15, but ILC3s acquire cytotoxicity also in the presence of IL-2 and IL-7.
In light of recent findings, it is possible that Eomes1 cells in NCR2 ILC3
cultures arise from tissue-resident CD1271CD1171NKp442 ILC
precursors.33 However, we demonstrate that human NKp441 bona
fide ILC3s from secondary lymphoid tissues can develop into functional
equivalents of NK cells, and this developmental pathway, which
demonstrates many similarities to NK-cell differentiation from stage 3
precursors,17,18 might provide cytotoxic protection at mucosal barriers.
Indeed, the development of innate cytotoxic cells from different
cellular sources seems to be occurring at barrier sites. In addition to
differentiation from innate lymphocytes, it has been demonstrated
that upon IL-15 stimulation, intraepithelial CD81 T cells exert
cytotoxic functions independent of the T-cell receptor (TCR) and
mainly via the prototypical activating NK-cell receptor NKG2D.34,35
These cells upregulate, along with NKG2C, NKp46, and NKp44, other
NK-cell receptors and can be observed in the gut of celiac disease
patients. Similarly, in the mouse, skin intraepithelial lymphocytes,
especially dendritic epidermal T cells, mediate their function through
target recognition via NKG2D.36,37 Signaling through their TCR was
attenuated at these sites and seemed to be required for survival,
whereas they efficiently secreted IFNg after stimulation with IL-12 and
IL-18, with and without IL-15 addition. TCR downregulation might also
have resulted in a proportion of putative ILC1 cells because they were
recently found to partially overlap with T-cell phenotypes in mass
cytometry11 and carry transcripts for TCR variable regions by single-cell
gene expression profiling.12 In addition to the emergence of NK-cell–like
populations from adaptive lymphocytes or ILC3s, as described here,
inflammation has been shown to drive differentiation of NK cells even in
Rag22/2Il2Rg2/2 mice and thus in the absence of IL-15 signaling.38
Similar to our study, this is induced by IL-12 and despite their immature
profile, these unconventional NK cells mediate tumor suppression.
The upregulation of a cytotoxic machinery in cells traditionally seen
as noncytotoxic is not exclusive to ILC3s. Adaptive CD41 Th cells
can also upregulate cytotoxicity, especially during chronic viral
infections.39-41 As shown for ILC3 differentiation in this study,
Eomes expression seems to be required for CD41 T cells to acquire
cytotoxicity42-44 and these cytolytic CD41 T cells also upregulate
CD94 and NKG2A.45,46 However, in contrast to induction of
cytotoxicity via IL-12, mainly IL-2 has been implicated in this
process.43 Thus, Eomes-dependent cytotoxicity can be induced in
both innate and adaptive lymphocyte populations, and type
1–inducing proinflammatory conditions favor its development.
These considerations suggest that an immunologically important
effector function, like Eomes-dependent cytotoxicity, can develop in
a variety of innate and adaptive lymphocyte populations due to
inflammatory conditions, such as, for example, chronic viral
infections. According to our data, ILC3s are not exempt from
differentiation to cytotoxic NK-cell–like lymphocytes, primarily after
stimulation with IL-12 and IL-15. They might even be exceptionally
well localized at mucosal barriers to exert cytotoxicity against virus-
infected and tumor cells at these sites and could be harnessed
during vaccination by the right choice of adjuvant.
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